Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]-FMH3 is a diagnostic radiopharmaceutical developed as a highly specific positron emission tomography (PET) imaging biomarker for the histamine H3 receptor. It is used in research to visualize and quantify H3 receptor activity in the brain, particularly for studies related to neurodegenerative diseases such as Alzheimer's disease. The mechanism of action involves acting as a PET tracer that binds selectively to the histamine H3 receptor, allowing non-invasive imaging of its distribution and occupancy in vivo. Initial development was by the Institute for Neurodegenerative Disorders, with early clinical studies demonstrating promising brain uptake and specificity for H3 receptors in both human and non-human primates[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]-FMH3.